Analysts Set Definitive Healthcare Corp. (NASDAQ:DH) Price Target at $5.35

Shares of Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) have earned a consensus rating of "Hold" from the twelve ratings firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $5.35.

DH has been the topic of a number of research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Barclays lowered their target price on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a report on Monday, March 3rd. Finally, The Goldman Sachs Group dropped their target price on Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th.

Definitive Healthcare Price Performance

Shares of Definitive Healthcare stock traded down $0.07 during trading on Friday, reaching $2.77. 499,578 shares of the company's stock were exchanged, compared to its average volume of 854,674. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. Definitive Healthcare has a 1-year low of $2.15 and a 1-year high of $7.47. The company has a market cap of $299.06 million, a P/E ratio of -0.89, a PEG ratio of 4.06 and a beta of 1.48. The firm's 50-day moving average price is $2.79 and its 200 day moving average price is $3.92.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The company had revenue of $62.29 million during the quarter, compared to the consensus estimate of $60.60 million. As a group, research analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current year.

Institutional Investors Weigh In On Definitive Healthcare

Hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its stake in Definitive Healthcare by 20.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company's stock valued at $85,000 after purchasing an additional 3,496 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Definitive Healthcare by 9.7% during the fourth quarter. Principal Financial Group Inc. now owns 43,960 shares of the company's stock worth $181,000 after acquiring an additional 3,874 shares in the last quarter. Rhumbline Advisers increased its position in shares of Definitive Healthcare by 5.2% during the fourth quarter. Rhumbline Advisers now owns 81,316 shares of the company's stock worth $334,000 after acquiring an additional 4,034 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of Definitive Healthcare by 18.1% in the 4th quarter. Canada Pension Plan Investment Board now owns 29,300 shares of the company's stock worth $120,000 after acquiring an additional 4,500 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Definitive Healthcare by 6.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company's stock valued at $334,000 after acquiring an additional 4,748 shares in the last quarter. 98.67% of the stock is currently owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.